Page 14 - Source Gt Biopharma Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Source gt biopharma inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Source Gt Biopharma Inc Today - Breaking & Trending Today

GT Biopharma Reports Fourth Quarter and Year End 2020 Results and Business Update

GT Biopharma Reports Fourth Quarter and Year End 2020 Results and Business Update
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Samir Taneja , Julie Seidel , Cytovance Biologics , Michael Handelman , Philip Werthman , Rajesh Shrotriya , Greg Berk , Susan Roush , Jeffreys Miller , Anthonyj Cataldo , David Castaneda , Beverly Hills , Michael Breen , Brucej Wendel , Iovance Biotherapeutics , Hospital Harvard Medical School , Company Scientific , Stern Investor Relations Inc , Source Gt Biopharma Inc , Exchange Commission , American Society Of Hematology , Development Expenses , University Of Wisconsin , Leadership Team , University Of Minnesota ,

GT Biopharma Announces GTB-3550 TriKE™ Monotherapy Rescues and Restores NK Cell Immune Surveillance in Relapsed/Refractory AML and MDS Cancer Patients

Share this article
Share this article
BEVERLY HILLS, Calif., April 12, 2021 /PRNewswire/ GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company s proprietary NK cell engager (TriKE™) protein biologic technology platform, announced today additional interim results from its GTB-3550 TriKE™ first-in-human Phase I/II clinical trial for the treatment of high-risk myelodysplastic syndromes (MDS) and refractory/relapsed acute myeloid leukemia (AML).
Additional results show GTB-3550 TriKE™ monotherapy is able to rescue the patient s otherwise exhausted/inhibited/non-functional endogenous NK cell population and target direct killing of the patient s AML and MDS cancer cells without the need for the co-administration addition of supplemental progenitor-derived or autologous/allogenic engineered NK cells. ....

United States , Julie Seidel , Anthonyj Cataldo , David Castaneda , Beverly Hills , Susan Roush , Stern Investor Relations Inc , National Cancer Institute , Source Gt Biopharma Inc , Exchange Commission , University Of Minnesota , Gt Biopharma Inc , Bone Marrow Blast Levels Resulting , Allogenic Cell Therapy , Treated Respond , Chief Executive , Securities Act , Investor Relations , Media Relations , ஒன்றுபட்டது மாநிலங்களில் , ஜூலி சீடல் , டேவிட் கஷ்டனேடா , பெவர்லி மலைகள் , சூசன் ரஷ் , கடுமையான முதலீட்டாளர் உறவுகள் இன்க் , தேசிய புற்றுநோய் நிறுவனம் ,

GT Biopharma Announces Enrollment Of Patient 10 in GTB-3550 TriKE™ Phase I/II Clinical Trial

Press release content from PR Newswire. The AP news staff was not involved in its creation.
GT Biopharma Announces Enrollment Of Patient 10 in GTB-3550 TriKE™ Phase I/II Clinical Trial
April 8, 2021 GMT
GT Biopharma Logo
BEVERLY HILLS, Calif., April 8, 2021 /PRNewswire/ GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary NK cell engager (TriKE™) protein biologic technology platform, is pleased to announce the enrollment of Patient 10 in its GTB-3550 TriKE™ first-in-human Phase I/II clinical trial for the treatment of high-risk myelodysplastic syndromes (MDS) and refractory/relapsed acute myeloid leukemia (AML). Patient 10 will be dosed at 100mcg/kg/day. ....

United States , Julie Seidel , Anthonyj Cataldo , David Castaneda , Beverly Hills , Susan Roush , Prnewswire Gt Biopharma Inc , Stern Investor Relations Inc , National Cancer Institute , Source Gt Biopharma Inc , Exchange Commission , University Of Minnesota , Gt Biopharma Inc , Bone Marrow Blast , Allogenic Cell Therapy , Chief Executive , Clinical Trial , Securities Act , Investor Relations , ஒன்றுபட்டது மாநிலங்களில் , ஜூலி சீடல் , டேவிட் கஷ்டனேடா , பெவர்லி மலைகள் , சூசன் ரஷ் , கடுமையான முதலீட்டாளர் உறவுகள் இன்க் , தேசிய புற்றுநோய் நிறுவனம் ,

GT Biopharma's TriKE™ Interim Clinical Trial Results Presented At Innate Killer Summit 2021

GT Biopharma's TriKE™ Interim Clinical Trial Results Presented At Innate Killer Summit 2021
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

United States , Julie Seidel , Anthony Cataldo , Jeffreys Miller , David Castaneda , Beverly Hills , Susan Roush , Prnewswire Gt Biopharma Inc , Stern Investor Relations Inc , National Cancer Institute , Source Gt Biopharma Inc , Exchange Commission , University Of Minnesota , Gt Biopharma Inc , Masonic Cancer Center , Deputy Director , Consulting Chief Medical Officer , Innate Killer Summit , Off The Shelf Strategies , Increase Activity , Bone Marrow Blast , Allogenic Cell Therapy , Bone Marrow Blast Levels , Cytokine Release Syndrome , Maximum Tolerated Dose , Clin Cancer ,

GT Biopharma's TriKE™ Interim Clinical Trial Results Presented At Innate Killer Summit 2021

GT Biopharma's TriKE™ Interim Clinical Trial Results Presented At Innate Killer Summit 2021
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.

United States , Julie Seidel , Anthony Cataldo , Jeffreys Miller , David Castaneda , Beverly Hills , Susan Roush , Prnewswire Gt Biopharma Inc , Stern Investor Relations Inc , National Cancer Institute , Source Gt Biopharma Inc , Exchange Commission , University Of Minnesota , Gt Biopharma Inc , Masonic Cancer Center , Deputy Director , Consulting Chief Medical Officer , Innate Killer Summit , Off The Shelf Strategies , Increase Activity , Bone Marrow Blast Levels , Allogenic Cell Therapy , Cytokine Release Syndrome , Maximum Tolerated Dose , Clin Cancer , Chief Executive Officer ,